220 related articles for article (PubMed ID: 36029651)
1. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
2. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
3. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of margetuximab plus chemotherapy
Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
[TBL] [Abstract][Full Text] [Related]
7. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Tabernero J; Shen L; Elimova E; Ku G; Liu T; Shitara K; Lin X; Boyken L; Li H; Grim J; Ajani J
Future Oncol; 2022 Sep; 18(29):3255-3266. PubMed ID: 36000541
[TBL] [Abstract][Full Text] [Related]
8. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma.
Catenacci DVT; Chung HC; Shen L; Moehler M; Yoon HH; Rosales MK; Kang YK
ESMO Open; 2022 Feb; 7(1):100360. PubMed ID: 34973512
[TBL] [Abstract][Full Text] [Related]
10. Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Yamaguchi K; Minashi K; Sakai D; Nishina T; Omuro Y; Tsuda M; Iwagami S; Kawakami H; Esaki T; Sugimoto N; Oshima T; Kato K; Amagai K; Hosaka H; Komine K; Yasui H; Negoro Y; Ishido K; Tsushima T; Han S; Shiratori S; Takami T; Shitara K
Cancer Sci; 2022 Aug; 113(8):2814-2827. PubMed ID: 35701865
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S; Anandappa G; Capdevila J; Dahan L; Evesque L; Kim S; Saunders MP; Gilbert DC; Jensen LH; Samalin E; Spindler KL; Tamberi S; Demols A; Guren MG; Arnold D; Fakih M; Kayyal T; Cornfeld M; Tian C; Catlett M; Smith M; Spano JP
ESMO Open; 2022 Aug; 7(4):100529. PubMed ID: 35816951
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS; Im SA; Cardoso F; Cortés J; Curigliano G; Musolino A; Pegram MD; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Kaufman B; Yerushalmi R; Fasching PA; Nordstrom JL; Bonvini E; Koenig S; Edlich S; Hong S; Rock EP; Gradishar WJ;
JAMA Oncol; 2021 Apr; 7(4):573-584. PubMed ID: 33480963
[TBL] [Abstract][Full Text] [Related]
14. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Catenacci DV; Kang YK; Uronis HE; Lee KW; Ng MC; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Oh DY; Yen J; Odegaard JI; Lagow E; Li D; Sun J; Kaminker P; Moore PA; Rosales MK; Park H
Oncology (Williston Park); 2023 Apr; 37(4):176-183. PubMed ID: 37104758
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
19. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
[TBL] [Abstract][Full Text] [Related]
20. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
